Teratogenic effects of silymarin on mouse fetuses

Publish Year: 1395
نوع سند: مقاله ژورنالی
زبان: English
View: 356

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_AJP-6-5_008

تاریخ نمایه سازی: 1 مهر 1398

Abstract:

Objective: Silybum marianum has been used for centuries in herbal medicine for treatment of liver diseases. Currently, there is no data available on the possible effects of silymarin on fetal development. This study aimed to investigate the teratogenic effect of silymarin on BALB/c mice fetuses. Materials and Methods: A total of 40 pregnant mice were divided into 4 groups of 10 mice each. Three groups received silymarin at three different doses of 50, 100 and 200 mg/kg/day during gestational days (GDs). The control group received normal saline and tween (solvent). Dams were sacrificed on GD 18 and all fetuses were examined for gross malformations, size and body weight. Malformed fetuses were double stained with alizarin red and alcian blue. Results: Silymarin administration at all doses resulted in reduction of the mean fetal body weights. The abnormalities included limb, vertebral column and craniofacial malformations. Craniofacial malformations were the most common abnormalities, but they were not observed in a dose-dependent manner. The percentage of fetal resorption significantly increased (up to 15%) in all treatment groups. Conclusion: Based on our results, silymarin, especially at high doses can lead to fetal resorption, intrauterine growth retardation and limb, vertebral column and craniofacial abnormalities. More precise studies should be conducted about the teratogenic effects of herbal medicine investigating the underlying mechanisms. Thus, caution should be taken when administering S. marianum to pregnant woman.

Authors

Mahbobe Gholami

Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Seyed Adel Moallem

Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Mohammad Afshar

Department of Anatomy, Birjand University of Medical Sciences, Birjand, Iran

Sakineh Amoueian

Department of Pathology, Imam-Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Afshar, M, Moallem S A, Mohammadpour A H, Shiravi A, ...
  • Ahmadi-Ashtiani, H, Allameh A, Rastegar H, Soleimani M,Barkhordari E. 2012. ...
  • Ahmadi-ashtiani, H, Rezazadeh S, Safipourian K, Afraz K, Khaki A,Rastegar ...
  • Badawy, G, El-Sayyad H L,Al-Shahar E E. 2011. Maternal and ...
  • Burdan, F, Dudka J, Szumilo J, Korobowicz A,Klepacz L. 2003. ...
  • Burdan, F, Pliszczynska-Steuden M, Rozylo-Kalinowska I, Chalas A, Rozylo T ...
  • Burdan, F, Szumilo J,Klepacz R. 2009. Maternal toxicity of nonsteroidal ...
  • Campos, R, Garrido A, Guerra R,Valenzuela A. 1989. Silibinin dihemisuccinate ...
  • Chan, L Y, Chiu P Y, Siu S S,Lau T ...
  • Etemad, L, Jafarian A H,Moallem S A. . Pathogenesis of ...
  • Fraschini, F, Demartini G,Esposti D. . Pharmacology of Silymarin. Clin ...
  • Fukushima, R, Kanamori S, Hirashiba M, Hishikawa A, Muranaka R ...
  • Giannola, C, Buogo F, Forestiere G, Scaffidi L, Ferrigno V,Scaffidi ...
  • Gilroy, D W, Tomlinson A, Greenslade K, Seed M P,Willoughby ...
  • Karimi, G, Vahabzadeh M, Lari P, Rashedinia M,Moshiri M. 2011. ...
  • Kasim, M J, Zheen A A, Intesar T N,Saad Abdul ...
  • Kaur, A K, Wahi A K, Brijesh K, Bhandari A,Prasad ...
  • Kimmel, C A,Trammell C. 1981. A rapid procedure for routine ...
  • Mahabady, M K,Varzi H N. 2011. Prophylactic Effects of Silymarin ...
  • Malekinejad, H, Taheri-Broujerdi M, Moradi M,Tabatabaie S H. 2011. Silymarin ...
  • Mallikarjuna, G, Dhanalakshmi S, Singh R P, Agarwal C,Agarwal R. ...
  • Metcalfe, A D, Hunter H R, Bloor D J, Lieberman ...
  • Muriel, P, Garciapina T, Perez-Alvarez V,Mourelle M. 1992. Silymarin protects ...
  • Nwadinigwe, C U,Anyaehie U E. 2007. Effects of cyclooxygenase inhibitors ...
  • Polyak, S J, Ferenci P,Pawlotsky J M. 2013. Hepatoprotective and ...
  • Pradhan, S C,Girish C. 2006. Hepatoprotective herbal drug, silymarin from ...
  • Sharma, m, Anwer T, Pillai K K, Haque S H, ...
  • Sorní, C, Sánchez R, Pellicer P,Andrés J P. 2005. Leflunomide: ...
  • Torchinsky, A, Fein A,Toder V. 2005. Teratogen-Induced Apoptotic Cell Death: ...
  • Urban, M. 2000. COX-2 specific inhibitors offer improved advantages over ...
  • Woo, S M, Min K J, Kim S, Park  J ...
  • نمایش کامل مراجع